A Phase 3 interventional study of Onexton and Clindamycin/benzoyl peroxide gel in Acne Vulgaris, sponsored by Actavis Inc.. Completed at 17 sites in United States. Open to participants aged 12 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-27.
Sponsored by Actavis Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing clindamycin in Acne Vulgaris — 1 open to participants now, 2 under way, none of them phase 3. Clindamycin · Acne Vulgaris.
Among the 34 studies testing clindamycin in Acne Vulgaris, this one is the 8th largest by enrollment, is one of 5 that started in 2015, is one of 9 in phase 3, and was the 30th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →1 of the 34 studies testing clindamycin in Acne Vulgaris is open now, in 1 country. Recruiting first, the newest first:
Centre for Human Drug Research, Netherlands · Sites in Netherlands
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
Clindamycin: first FDA approval 1970 (CLEOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 9 · Phase 4 16
First in 2005; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 862 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 117 across the 34 interventional studies. Of the 30 that completed or were terminated, 19 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Actavis Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Actavis Inc. is the lead sponsor of 95 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 9 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing clindamycin in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Actavis has developed a generic formulation of clindamycin 1.2% and benzoyl peroxide 3.75% gel. This study is designed to evaluate the safety and efficacy of this formulation in subjects with Acne Vulgaris
This is a randomized, double blind, three-arm, parallel group, placebo control bioequivalence study with clinical endpoint, at multiple study sites, designed to establish bioequivalence of clindamycin 1.2% and benzoyl peroxide 3.75% gel of Actavis and Onexton® (clindamycin 1.2% and benzoyl peroxide 3.75%) gel in the treatment of subjects with Acne Vulgaris.
The primary objective is to evaluate the bioequivalence of a generic of clindamycin 1.2% and benzoyl peroxide 3.75% gel to Onexton® in the treatment of subjects with acne vulgaris.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clindamycin 1.2% and benzoyl peroxide 3.75% topical gel Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
Drug: Onexton
Generic clindamycin 1.2% and benzoyl peroxide 3.75% topical gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
Drug: Clindamycin/benzoyl peroxide gel
A vehicle gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
Drug: Placebo
Drug pages: Clindamycin · Benzoyl Peroxide
Topical gel for treating acne
Also known as: Clindamycin/benzoyl peroxide gel
Drug pages: Clindamycin · Benzoyl Peroxide
Generic Clindamycin/benzoyl peroxide gel for treating acne
Also known as: Clindamcyin Phosphate, BPO
Vehicle gel used as a placebo
Also known as: Vehicle
Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts
Percent change from baseline to Week 12 (Day 84) in the inflammatory (papules and pustules) lesion count in PP Population.
Time frame: 12 weeks
Percent Change in the Non-Inflammatory (Open and Closed Comedomes) Lesion Counts
One of the co-primary endpoints was the percent change from baseline to Week 12 (Day 84) in the non-inflammatory (open and closed comedones) lesion counts in PP Population.
Time frame: 12 weeks
Number of Subjects With Treatment Success at Week 12
The secondary efficacy endpoint was the IGA score, expressed in terms of proportion of subjects with treatment success or failure at Week 12, where "success" was defined as an IGA score that was at least 2 grades less than the baseline assessment.
Time frame: 12 weeks
| Milestone | Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel | Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel) | Vehicle Gel |
|---|---|---|---|
| Started | 347 | 345 | 170 |
| Safety population | 329 | 328 | 161 |
| Mitt population | 325 | 325 | 160 |
| Pp population | 253 | 255 | 122 |
| Completed | 282 | 285 | 141 |
| Not completed | 65 | 60 | 29 |
| Withdrew: Withdrawal by subject | 10 | 5 | 6 |
| Withdrew: Physician decision | 2 | 1 | 0 |
| Withdrew: Adverse event | 1 | 4 | 1 |
| Withdrew: Protocol violation | 0 | 3 | 1 |
| Withdrew: Prohibited medication | 12 | 9 | 5 |
| Withdrew: More than 3 applications missed | 6 | 8 | 1 |
| Withdrew: Lost to follow-up | 31 | 28 | 13 |
| Withdrew: Pregnancy | 2 | 0 | 1 |
| Withdrew: Other | 1 | 2 | 1 |
Percent change from baseline to Week 12 (Day 84) in the inflammatory (papules and pustules) lesion count in PP Population.
| percentage of change | Generic Clindamycin and Benzoyl Peroxide | Reference Onexton (Clindamycin and Benzoyl Peroxide) | Vehicle Gel |
|---|---|---|---|
| Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts | -63.81 ± 36.791 | -67.56 ± 28.405 | -53.78 ± 40.138 |
One of the co-primary endpoints was the percent change from baseline to Week 12 (Day 84) in the non-inflammatory (open and closed comedones) lesion counts in PP Population.
| percentage of change | Generic Clindamycin and Benzoyl Peroxide | Reference Onexton (Clindamycin and Benzoyl Peroxide) | Vehicle Gel |
|---|---|---|---|
| Percent Change in the Non-Inflammatory (Open and Closed Comedomes) Lesion Counts | -49.58 ± 40.747 | -49.50 ± 32.872 | -37.50 ± 40.261 |
The secondary efficacy endpoint was the IGA score, expressed in terms of proportion of subjects with treatment success or failure at Week 12, where "success" was defined as an IGA score that was at least 2 grades less than the baseline assessment.
| participants | Generic Clindamycin and Benzoyl Peroxide | Reference Onexton (Clindamycin and Benzoyl Peroxide) | Vehicle Gel |
|---|---|---|---|
| Success | 54 | 60 | 13 |
| Failure | 199 | 195 | 109 |
Collected over Baseline to 12 Weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel | 0/329 (0%) | 4/329 (1.2%) | 197/329 (59.9%) |
| Reference Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75) | 0/328 (0%) | 0/328 (0%) | 211/328 (64.3%) |
| Vehicle Gel | 0/161 (0%) | 0/161 (0%) | 92/161 (57.1%) |
| Event | Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel | Reference Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75) | Vehicle Gel |
|---|---|---|---|
| Bipolar disorderPsychiatric disorders | 1/329 | 0/328 | 0/161 |
| Cranio-cerebral injuryInjury, poisoning and procedural complications | 1/329 | 0/328 | 0/161 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/329 | 0/328 | 0/161 |
| Allergy to arthropod stingImmune system disorders | 1/329 | 0/328 | 0/161 |
| Event | Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel | Reference Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75) | Vehicle Gel |
|---|---|---|---|
| Dry skinSkin and subcutaneous tissue disorders | 127/329 | 138/328 | 56/161 |
| PruritusSkin and subcutaneous tissue disorders | 59/329 | 70/328 | 31/161 |
| ErythemaSkin and subcutaneous tissue disorders | 55/329 | 58/328 | 31/161 |
| Skin burning sensationSkin and subcutaneous tissue disorders | 34/329 | 27/328 | 11/161 |
| Skin irritationSkin and subcutaneous tissue disorders | 17/329 | 23/328 | 10/161 |
| Skin erosionSkin and subcutaneous tissue disorders | 12/329 | 22/328 | 8/161 |
| AcneSkin and subcutaneous tissue disorders | 9/329 | 9/328 | 10/161 |
| Facial painGeneral disorders | 16/329 | 17/328 | 5/161 |
| Application site drynessGeneral disorders | 11/329 | 9/328 | 2/161 |
| PainGeneral disorders | 8/329 | 3/328 | 0/161 |
| Age, Continuous(years) | Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel | Reference Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75) | Vehicle Gel | Total |
|---|---|---|---|---|
| Mean | 20.6 ± 7.56 | 20.4 ± 7.04 | 20.1 ± 6.92 | 20.4 ± 7.23 |
| Sex: Female, Male(Participants) | Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel | Reference Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75) | Vehicle Gel | Total |
|---|---|---|---|---|
| Female | 204 | 217 | 105 | 526 |
| Male | 125 | 111 | 56 | 292 |
| Ethnicity (NIH/OMB)(Participants) | Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel | Reference Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75) | Vehicle Gel | Total |
|---|---|---|---|---|
| Hispanic or Latino | 76 | 89 | 45 | 210 |
| Not Hispanic or Latino | 253 | 239 | 116 | 608 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel | Reference Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75) | Vehicle Gel | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 4 | 2 | 1 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 82 | 86 | 42 | 210 |
| White | 225 | 224 | 110 | 559 |
| More than one race | 18 | 15 | 8 | 41 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
The record gives a start of May 2015, a primary completion of Oct 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2020, 4 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Clindamycin · Benzoyl Peroxide